Table 2.
Selected examples of liposomal formulation used in the in vivo model for treatment of CVD.
| Therapeutics Encapsulated | In vivo Model | Outcome | Ref. |
|---|---|---|---|
| Simvastatin/Alendronate | Carotid-injured rat model | Suppressed neointimal formation | [171,172] |
| Nitric oxide | Carotid-injured rabbit model | Suppressed neointimal formation | [173] |
| Berberine | Myocardial infarction murine model | Improvement of cardiac function | [152] |
| VEGF | Myocardial infarction rat model | Improved cardiac functions | [174] |
| Cyclopentenone prostaglandin | Hyperlipemic diet atherosclerotic murine model | Vascular injuries recovery | [175] |
| Fumagillin | Hyperlipemic diet atherosclerotic murine model | Reduced atherosclerotic lesions | [176] |